Aya Mohamed, Medical Oncologist, Associate Lecturer of Medical Oncology, Member of ASCO, shared a post on X:
“Oncotype DX in early HR+/HER2− BC:
Recurrence Score drives adjuvant decisions beyond clinicopathologic features, enabling precise chemo escalation/de-escalation despite discordance.”
Title: Clinical Impact and Clinicopathologic Correlations of Oncotype DX in Hormone Receptor–Positive/HER2–Negative Early Breast Cancer: Real-World Evidence From a Large Brazilian Cohort (GBECAM 0520)
Authors: Leandro Jonata de Carvalho Oliveira, Daniella Castro Araújo, Júlio Antonio Pereira de Araújo, Daniela Dornelles Rosa, Artur Katz, Daniele Assad-Suzuki, Daniel Argolo, Solange Moraes Sanches, Laura Testa, José Bines, Rafael Aliosha Kaliks, Debora de Melo Gagliato, Romualdo Barroso-Sousa, Tatiana Strava Corrêa, Andrea Kazumi Shimada, Carlos Henrique dos Anjos, Rudinei Linck, Thais Baccili Cury Megid, Daniel Negrini Batista, Daniel Musse Gomes, Marcelle Goldner Cesca, Débora Gaudêncio, Larissa Matos Almeida Moura, Renata Colombo Bonadio, Zenaide Silva de Souza, Juliana Rodrigues Beal, Mario Machado Lopes, Leticia Telles Sales, Júlia Leal Franco Parisi Marlière, Max Senna Mano
10 Essential Breast Oncology Posts You Can’t Miss This Week
